In the last several years, Tau-directed therapies have gained more interest as a strategy for treating Alzheimer’s Disease.
reMYND’s Tau.P301L mice used to demonstrate efficacy of antibody treatment on behaviour and pathological read-outs
BMS publishes paper in collaboration with reMYND showing dose-dependent effects of donepezil on brain Abeta and cognition in MWM
We would like to bring to your attention a recent publication titled “Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer’s disease”.
Roche presents preclinical efficacy data gathered in collaboration with reMYND’s CRO on a promising combo Alzheimer treatment
Press release | Roche presents preclinical efficacy data gathered in collaboration with reMYND’s CRO on a promising combo Alzheimer treatment
reMYND launches a project aimed at improving the predictability of preclinical Alzheimer models as part of the prestigious Marie-Curie International Training Network NPlast
Press release | reMYND NV announced today its project in NPlast, a prestigious International Training Network funded by the European Commission that is to be launched April 27-28th 2012 at the Leibniz-Institut für Neurobiologie in Magdeburg, Germany.
Ajit Shetty strengthens reMYND’s Board of Directors
Press release | reMYND NV today announced that its shareholders have elected Ajit Shetty to join the company’s 4-person Board as an Independent Director.